Conferences
Advertisement
Pierluigi Porcu, MD, discusses the phase II Tellomak trial and how nurses can help patients manage this rare disease.
Amy Pierre, RN, BSN, ANP-BC, reflects on highlights from ASH 2024 and why it's critical for advanced practitioners to attend.
An expert in pediatric GVHD shares his hopes and projections for the future of GVHD treatment and research.
Samantha Shenoy, NP, shares why it's important for nurses and APPs to consider attending the annual meeting.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, discusses the significance of ASH 2024.
The CLL12 trial included patients with treatment-naive, asymptomatic, early-stage chronic lymphocytic leukemia.
Researchers evaluated treatment patterns, blood count control, and use of phlebotomy in patients with polycythemia vera.
Lisa Hwa, APRN, CNP, DNP, MS, discusses her work with the ASH Medical Educators Institute and her conference experience.
Amy Pierre, RN, BSN, ANP-BC, shares insights and key action items from her ASH 2024 presentation on the topic.
Richard Newcomb, MD, shares insights from his ASH 2024 presentation and explains why nurses play a major role in outcomes.
Irwin Walker, MBBS, shares how he's seen the meeting evolve since his first time attending in 1971.
An ASH 2024 presentation of data from the Myelofibrosis and Essential Thrombocythemia Observational Study provided insights.
The study highlighted that adding abatacept to CNI/MTX-based GVHD prophylaxis showed durable central outcomes post-HCT.
Risk factors for GVHD and its severity differ by donor type following allogeneic SCT with post-transplant PTCy prophylaxis.
Patients with pulmonary comorbidities and a history of smoking are at increased risk for chronic GVHD.
Dr. Bose joined Cancer Nursing Today at ASH 2024 to share insights on using anemia-supporting medications with ruxolitinib.
Piyanuch Kongtim, MD, PhD, shares insights from work she presented at the 2024 ASH Annual Meeting.
Samantha Shenoy, NP, speaks about her experience at the meeting and key highlights in multiple myeloma research.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, explains key takeaways from her myeloma research at ASH 2024.
Irwin Walker, MBBS, joined Cancer Nursing Today at ASH 2024 to share his insights on the pilot trial and the next steps.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.